Business ❯ Healthcare ❯ Pharmaceuticals

Gene Therapy

Duchenne Muscular Dystrophy Sarepta Therapeutics Huntington's Disease Ophthalmology Vision Loss Clinical Trials Regulatory Affairs Acquisitions

Taysha Advances Rett Gene Therapy Program With Pivotal Dosing, FDA Alignment and Q2 Data Timeline

FDA feedback supports a streamlined route to a potential BLA.

FDA Meeting Minutes Undercut uniQure’s Plan to File Huntington’s Gene Therapy for Approval

Lilly Licenses MeiraGTx Eye Gene Therapy in Deal Worth Up to $475 Million

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

FDA Lifts Hold on Elevidys Shipments to Ambulatory Duchenne Patients

Sarepta Temporarily Halts Elevidys Shipments Under FDA Request

Sarepta Shares Plummet on FDA Review of Elevidys Following Third Patient Death

AMD Shares Surge on Next-Gen MI400 AI Chips and Helios Server Rack